
The pitch lasts twenty minutes. The science may already be carrying years of experiments, animal studies, regulatory preparation and decisions about which patients should reach the work first.
Longevity Biotech Pitch Night brings that longer record into a New York investor room on November 19. The Longevity Investor Network and Lifespan Research Institute are convening an approval-required evening for investors to hear directly from companies working across cardiovascular disease, mitochondrial disorders, regenerative delivery and engineered heart tissue.
Repair Biotechnologies, Unmask Therapeutics, Havia Bio and Repairon are listed in the current program.
Repair Biotechnologies is developing a cholesterol-degrading platform intended to clear toxic free cholesterol inside cells. Unmask Therapeutics is working on a small-molecule treatment for genetic mitochondrial disease. Havia Bio is building a delivery platform designed to keep regenerative therapies at the target site longer. Repairon is advancing engineered human heart-muscle patches already studied in patients.
Those programs do not move on the same clock. The evidence, regulatory path and capital requirement change with the biology. Bringing them into the same investor room makes the comparison useful only when each company can keep its own development record intact.
Use the official page for current access, presenting-company and venue details.
2026-11-19; 5:00-9:15 PM ET.
Private New York venue, New York.